Patents by Inventor Ji-Eun Jung
Ji-Eun Jung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240152724Abstract: The present invention provides a scalable digital twin system structure and a scalable digital twin service method that are capable of, based on a digital twin, performing real-time control of the real world while providing information required for the user to determine the optimal countermeasure in solve real-world problems in stages, thereby helping rapidly solve problems of the real-world. In order to preemptively respond to the real-world problems by providing decision support information with improved reliability according to a timeline based on a digital twin of a scalable structure, the operation of the digital twin is divided into several stages according to complexity and a result of each stage is transferred to an application service and the next stage, so that as the stage becomes higher, a more reliable result can be provided.Type: ApplicationFiled: November 7, 2022Publication date: May 9, 2024Inventors: Mi Suk LEE, Woo-Sug JUNG, Ji Eun KIM, Hyunjin KIM, Ki-Sook CHUNG
-
Patent number: 11975076Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.Type: GrantFiled: November 12, 2021Date of Patent: May 7, 2024Assignee: LegoChem Biosciences, Inc.Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
-
Publication number: 20240115642Abstract: The present invention relates to a composition for preventing hair loss or promoting hair growth containing a milk thistle flower extract as an active ingredient. More specifically, the present invention relates to a cosmetic composition, pharmaceutical composition and food composition containing a milk thistle flower extract as an active ingredient, which are able to promote hair growth by inducing the proliferation of dermal papilla cells reduced due to senescence, and activate dermal papilla cells by inhibiting the senescence of dermal papilla cells through inhibition of the activity of senescence-associated ?-galactosidase (SA-?-Gal) and the production of senescence-associated secretory phenotypes, thereby preventing hair loss or promoting hair.Type: ApplicationFiled: August 18, 2022Publication date: April 11, 2024Inventors: Ji Eun WOO, Seoung Woo SHIN, Eun Sun JUNG, Deok Hoon PARK
-
Patent number: 11763955Abstract: Disclosed is a method of producing Tc-99m by using nuclear resonance fluorescence. More specifically, and a method of preparing Tc-99m by using nuclear resonance fluorescence includes irradiating a ground-state Tc-99 nucleus with a photon beam, thereby causing a nuclear transmutation to proceed such that the nucleus excited to high energy and then undergoes a transition to Tc-99m.Type: GrantFiled: September 18, 2017Date of Patent: September 19, 2023Assignee: Korea Hydro & Nuclear Power Co., Ltd.Inventors: Yonghee Kim, Jiyoung Lee, Seongdong Jang, Ur Rehman Haseeb, Eun Ki Lee, Young Ae Kim, Ji Eun Jung
-
Patent number: 11413353Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.Type: GrantFiled: November 23, 2016Date of Patent: August 16, 2022Assignee: LegoChem Biosciences, Inc.Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
-
Patent number: 11395133Abstract: An electronic device includes a wireless communication circuit, a secure element configured to store information, the information including a first identifier indicating the secure element and at least one second identifier indicating a profile for a wireless communication service provided by at least one cellular network, at least one processor, and a memory configured to store instructions. The instructions, when executed, cause the at least one processor to transmit the first identifier to a first external server, via the wireless communication circuit, receive a second identifier and a profile associated with the second identifier from the second external server via the wireless communication circuit and store the second identifier and the profile in the secure element, and receive a first request, including the second identifier, associated with management of the profile, from the first external server.Type: GrantFiled: December 19, 2018Date of Patent: July 19, 2022Assignee: Samsung Electronics Co., Ltd.Inventors: Sung Oh Kim, Jeong Don Kang, Jae Hyeon Seo, Sang Soo Lee, Sang Hwi Lee, Ji Eun Jung
-
Publication number: 20220218840Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.Type: ApplicationFiled: November 12, 2021Publication date: July 14, 2022Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
-
Publication number: 20220204560Abstract: The present invention relates to a novel oligopeptide, and a pharmaceutical composition for preventing or treating cancer, comprising same as an active ingredient. The oligopeptide of the present invention has an advantage in that the molecular weight thereof is less than that of an antibody, and thus the risk of an immune response is low, and it has better tissue permeability. The oligopeptide can exhibit the effect of inhibiting the proliferation of malignant tumors by selectively acting on cancer cells or cancer tissue.Type: ApplicationFiled: April 29, 2020Publication date: June 30, 2022Inventors: Do Yong Jeon, Sang Hyeok Woo, Chang Hoon Moon, Ji Eun Jung, Hyun Hee Shin, Hyerim Lee, Jee Young Lee
-
Patent number: 11324102Abstract: Disclosed is an apparatus for extracting multiple laser Compton scattering (“LCS”) photon beams using a laser Compton scattering reaction, the apparatus including: a linear accelerator for accelerating an electron beam; and an LCS gamma ray generation module including an LCS gamma ray generator for irradiating a target with an LCS gamma ray generated by emitting laser light to an electron beam released from the linear accelerator and a bending magnet for adjusting a direction of the electron beam passed through the LCS gamma ray generator, wherein at least two LCS gamma ray generation modules are sequentially arranged to form a closed loop together with the linear accelerator.Type: GrantFiled: September 18, 2017Date of Patent: May 3, 2022Assignee: Korea Hydro & Nuclear Power Co., Ltd.Inventors: Yonghee Kim, Jiyoung Lee, Seongdong Jang, Ur Rehman Haseeb, Eun Ki Lee, Young Ae Kim, Ji Eun Jung
-
Patent number: 11173214Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.Type: GrantFiled: November 23, 2016Date of Patent: November 16, 2021Assignee: LegoChem Biosciences, Inc.Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
-
Patent number: 11167040Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.Type: GrantFiled: November 23, 2016Date of Patent: November 9, 2021Assignee: LegoChem Biosciences, Inc.Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
-
Publication number: 20200361989Abstract: Provided are a polypeptide having the activity of inhibiting autophagy in a cell, a composition for inhibiting autophagy in a cell, and particularly in a tumor cell, containing the polypeptide as an active ingredient, and a pharmaceutical composition containing the polypeptide, and more specifically, a composition for inhibiting autophagy in a cell containing a polypeptide inhibiting the control mechanism of autophagy as an active ingredient, and a pharmaceutical composition for preventing or treating a neoplastic disease or for inhibiting resistance to anticancer agents, containing the polypeptide.Type: ApplicationFiled: July 31, 2020Publication date: November 19, 2020Applicant: L-BASE CO., LTDInventors: Do Yong JEON, Chang Hoon MOON, Ji Eun JUNG
-
Publication number: 20200297865Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.Type: ApplicationFiled: November 23, 2016Publication date: September 24, 2020Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
-
Patent number: 10766926Abstract: Provided are a polypeptide having the activity of inhibiting autophagy in a cell, a composition for inhibiting autophagy in a cell, and particularly in a tumor cell, containing the polypeptide as an active ingredient, and a pharmaceutical composition containing the polypeptide, and more specifically, a composition for inhibiting autophagy in a cell containing a polypeptide inhibiting the control mechanism of autophagy as an active ingredient, and a pharmaceutical composition for preventing or treating a neoplastic disease or for inhibiting resistance to anticancer agents, containing the polypeptide.Type: GrantFiled: May 28, 2018Date of Patent: September 8, 2020Assignee: L-BASE CO., LTDInventors: Do Yong Jeon, Chang Hoon Moon, Ji Eun Jung
-
Publication number: 20200236767Abstract: Disclosed is an apparatus for extracting multiple laser Compton scattering photon (“LCS”) beams using a laser Compton scattering reaction, the apparatus including: a linear accelerator for accelerating an electron beam; and an LCS gamma ray generation module including an LCS gamma ray generator for irradiating a target with an LCS gamma ray generated by emitting laser light to an electron beam released from the linear accelerator and a bending magnet for adjusting a direction of the electron beam passed through the LCS gamma ray generator, wherein at least two LCS gamma ray generation modules are sequentially arranged to form a closed loop together with the linear accelerator.Type: ApplicationFiled: September 18, 2017Publication date: July 23, 2020Inventors: Yonghee KIM, Jiyoung LEE, Seongdong JANG, Ur Rehman HASEEB, Eun Ki LEE, Young Ae KIM, Ji Eun JUNG
-
Publication number: 20200234837Abstract: Disclosed is a method of producing Tc-99m by using nuclear resonance fluorescence. More specifically, the method of producing Tc-99m by using nuclear resonance fluorescence includes irradiating a ground-state Tc-99 nucleus with a photon beam, thereby causing a nuclear transmutation to proceed such that the nucleus is excited to high energy and then undergoes a transition to Tc-99m.Type: ApplicationFiled: September 18, 2017Publication date: July 23, 2020Inventors: Yonghee KIM, Jiyoung LEE, Seongdong JANG, Ur Rehman HASEEB, Eun Ki LEE, Young Ae KIM, Ji Eun JUNG
-
Publication number: 20200087344Abstract: Provided are a polypeptide having the activity of inhibiting autophagy in a cell, a composition for inhibiting autophagy in a cell, and particularly in a tumor cell, containing the polypeptide as an active ingredient, and a pharmaceutical composition containing the polypeptide, and more specifically, a composition for inhibiting autophagy in a cell containing a polypeptide inhibiting the control mechanism of autophagy as an active ingredient, and a pharmaceutical composition for preventing or treating a neoplastic disease or for inhibiting resistance to anticancer agents, containing the polypeptide.Type: ApplicationFiled: May 28, 2018Publication date: March 19, 2020Applicant: L-BASE CO., LTDInventors: Do Yong JEON, Chang Hoon MOON, Ji Eun JUNG
-
Publication number: 20190381185Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.Type: ApplicationFiled: November 23, 2016Publication date: December 19, 2019Applicant: LegoChem Biosciences, Inc.Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
-
Publication number: 20190191298Abstract: An electronic device includes a wireless communication circuit, a secure element configured to store information, the information including a first identifier indicating the secure element and at least one second identifier indicating a profile for a wireless communication service provided by at least one cellular network, at least one processor, and a memory configured to store instructions. The instructions, when executed, cause the at least one processor to transmit the first identifier to a first external server, via the wireless communication circuit, receive a second identifier and a profile associated with the second identifier from the second external server via the wireless communication circuit and store the second identifier and the profile in the secure element, and receive a first request, including the second identifier, associated with management of the profile, from the first external server.Type: ApplicationFiled: December 19, 2018Publication date: June 20, 2019Inventors: Sung Oh KIM, Jeong Don KANG, Jae Hyeon SEO, Sang Soo LEE, Sang Hwi LEE, Ji Eun JUNG
-
Publication number: 20190151465Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.Type: ApplicationFiled: November 23, 2016Publication date: May 23, 2019Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee